| Market Cap | 11.86M | P/E | - | EPS this Y | 59.70% | Ern Qtrly Grth | - |
| Income | -1.81M | Forward P/E | - | EPS next Y | 62.80% | 50D Avg Chg | -24.00% |
| Sales | 441.25k | PEG | - | EPS past 5Y | - | 200D Avg Chg | -24.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -75.00% |
| Recommedations | 2.50 | Quick Ratio | 1.54 | Shares Outstanding | 1.86M | 52W Low Chg | 7.00% |
| Insider Own | 19.37% | ROA | -95.59% | Shares Float | 1.50M | Beta | - |
| Inst Own | 3.02% | ROE | - | Shares Shorted/Prior | 54.30K/104.84K | Price | 2.13 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 3,300,662 | Target Price | 5.50 |
| Oper. Margin | -3,332.34% | Earnings Date | - | Volume | 241,386 | Change | -0.93% |
60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is headquartered in Washington, the District of Columbia.
| HC Wainwright & Co. | Neutral | Sep 13, 24 |
| HC Wainwright & Co. | Neutral | Aug 15, 24 |
| HC Wainwright & Co. | Neutral | Jun 6, 24 |
| HC Wainwright & Co. | Neutral | Apr 3, 24 |
| HC Wainwright & Co. | Neutral | Oct 20, 23 |
| Ascendiant Capital | Buy | Oct 2, 23 |